(238) Steroid-containing lipid NPs enable mRNA delivery while reducing inflammation in autoimmune disease

Introduction: Autoimmune diseases affect 5-10% of the population and are characterized by the loss of central immune tolerance, leading to self-reactivity and inflammation.[1] Emerging strategies aim to restore tolerance by introducing self-antigens in suppressive/tolerogenic environments; however, delivery of self-antigens in pre-existing inflammation is challenging due to the altered immune landscape.[2] Here, we engineer lipid nanoparticles (LNPs) to incorporate the FDA approved steroid triamcinolone to reduce inflammation while simultaneously delivering mRNA in mouse models of inflammation (Fig 1A).